FDA approves clinical study in Alzheimer patients

Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease.

The study will commence in the US together with Eisai Co., Ltd. The new treatment approach is expected to halt progression of the disease.